The tumor-selective cytotoxic effect of tumor necro-sis factor–related apoptosis-inducing ligand (TRAIL) makes TRAIL an attractive candidate as an anticancer agent. However, resistance to TRAIL poses a challenge in anticancer therapy with TRAIL. Therefore, character-izing the mechanisms of resistance and developing strategies to overcome the resistance are important steps toward successful TRAIL-mediated cancer ther-apy. In this study, we investigated mechanisms of ac-quired TRAIL resistance in a colon cancer DLD1 cell line. Compared with the TRAIL-susceptible DLD1 cell line, TRAIL-resistant DLD1/TRAIL-R cells have a low level of caspase-8 protein, but not its mRNA. Suppres-sion of caspase-8 expression by siRNA in parental DLD1 cells led to...
One of the key features of cancer cells is the ability to escape programmed cell death (apoptosis). ...
Recombinant human tumor necrosis factor–related apoptosis–inducing ligand (rhTRAIL) is being evaluat...
TRAIL has been shown to target tumor cells but not healthy cells in vitro. In addition, clinical stu...
The tumor-selective cytotoxic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRA...
AbstractThe tumor-selective cytotoxic effect of tumor necrosis factor-related apoptosis-inducing lig...
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers the apoptotic cascade in va...
Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. Intrinsic, as wel...
Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. Intrinsic, as wel...
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in man...
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine and a selective induc...
When the membrane-incorporated homotrimeric TRAIL ligand binds its death receptors (DR), trimerized ...
TRAIL is a member of the Tumor Necrosis Factor superfamily which was shown to be able to induce apop...
umor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to exert an unexpected...
Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) exhibits potent antitumour ac...
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising molecule for an...
One of the key features of cancer cells is the ability to escape programmed cell death (apoptosis). ...
Recombinant human tumor necrosis factor–related apoptosis–inducing ligand (rhTRAIL) is being evaluat...
TRAIL has been shown to target tumor cells but not healthy cells in vitro. In addition, clinical stu...
The tumor-selective cytotoxic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRA...
AbstractThe tumor-selective cytotoxic effect of tumor necrosis factor-related apoptosis-inducing lig...
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers the apoptotic cascade in va...
Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. Intrinsic, as wel...
Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. Intrinsic, as wel...
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in man...
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine and a selective induc...
When the membrane-incorporated homotrimeric TRAIL ligand binds its death receptors (DR), trimerized ...
TRAIL is a member of the Tumor Necrosis Factor superfamily which was shown to be able to induce apop...
umor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to exert an unexpected...
Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) exhibits potent antitumour ac...
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising molecule for an...
One of the key features of cancer cells is the ability to escape programmed cell death (apoptosis). ...
Recombinant human tumor necrosis factor–related apoptosis–inducing ligand (rhTRAIL) is being evaluat...
TRAIL has been shown to target tumor cells but not healthy cells in vitro. In addition, clinical stu...